Aclaris Therapeutics, Inc. (ACRS)
- Previous Close
1.1800 - Open
1.2000 - Bid 1.1700 x 100
- Ask 1.1800 x 100
- Day's Range
1.1650 - 1.2050 - 52 Week Range
0.5900 - 11.1200 - Volume
392,212 - Avg. Volume
977,744 - Market Cap (intraday)
83.736M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0900 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.84
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
www.aclaristx.com86
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACRS
Performance Overview: ACRS
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACRS
Valuation Measures
Market Cap
84.09M
Enterprise Value
-34.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.69
Price/Book (mrq)
0.59
Enterprise Value/Revenue
-1.03
Enterprise Value/EBITDA
0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
-248.28%
Return on Assets (ttm)
-31.90%
Return on Equity (ttm)
-48.47%
Revenue (ttm)
31.12M
Net Income Avi to Common (ttm)
-77.26M
Diluted EPS (ttm)
-1.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
128.17M
Total Debt/Equity (mrq)
2.45%
Levered Free Cash Flow (ttm)
-40.25M
Research Analysis: ACRS
Company Insights: ACRS
ACRS does not have Company Insights